Published in J Acquir Immune Defic Syndr on July 01, 2013
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med (2016) 3.82
Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One (2014) 2.85
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med (2014) 2.08
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis (2014) 2.05
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell (2016) 1.82
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis (2015) 1.71
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 1.61
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS (2015) 1.30
Minimal Awareness and Stalled Uptake of Pre-Exposure Prophylaxis (PrEP) Among at Risk, HIV-Negative, Black Men Who Have Sex with Men. AIDS Patient Care STDS (2015) 1.28
Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc (2015) 1.27
A paradigm shift: focus on the HIV prevention continuum. Clin Infect Dis (2014) 1.12
Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes. AIDS Behav (2016) 1.07
An action agenda for HIV and sex workers. Lancet (2014) 1.06
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS (2016) 0.99
Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDS (2014) 0.97
Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis. PLoS One (2014) 0.97
Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care (2014) 0.96
Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". AIDS Behav (2015) 0.95
Tailored combination prevention packages and PrEP for young key populations. J Int AIDS Soc (2015) 0.93
Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis (2014) 0.90
Biomedical prevention: state of the science. Clin Infect Dis (2014) 0.89
The current status of the use of oral medication to prevent HIV transmission. Curr Opin HIV AIDS (2015) 0.88
Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications. J Acquir Immune Defic Syndr (2017) 0.88
A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs. AIDS Patient Care STDS (2015) 0.86
Global HIV epidemiology: A guide for strategies in prevention and care. Curr HIV/AIDS Rep (2014) 0.85
Pre-exposure prophylaxis in Southern Africa: feasible or not? J Int AIDS Soc (2015) 0.83
Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role. J Acquir Immune Defic Syndr (2015) 0.82
Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. Curr Treat Options Infect Dis (2015) 0.81
Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses. J Acquir Immune Defic Syndr (2015) 0.80
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol (2014) 0.79
Antiretroviral chemoprophylaxis: state of evidence and the research agenda. Clin Infect Dis (2014) 0.79
Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women. Antimicrob Agents Chemother (2014) 0.79
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep (2017) 0.77
AIDS: The final chapter? AIDS Res Hum Retroviruses (2014) 0.77
Towards an integrated framework for accelerating the end for the global HIV epidemic among young people. Sex Educ (2014) 0.77
A scoping review and thematic analysis of social and behavioural research among HIV-serodiscordant couples in high-income settings. BMC Public Health (2015) 0.77
Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis (2016) 0.77
Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2015) 0.77
When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health Sex (2016) 0.76
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol. JMIR Res Protoc (2017) 0.75
Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities. Curr Opin HIV AIDS (2015) 0.75
Levels of intracellular phosphorylated tenofovir and emtricitabine correlate with natural substrate concentrations in peripheral blood mononuclear cells of persons prescribed daily oral TruvadaTM for HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2017) 0.75
"Life-Steps" for PrEP Adherence: Demonstration of a CBT-Based Intervention to Increase Adherence to Preexposure Prophylaxis (PrEP) Medication Among Sexual-Minority Men at High Risk for HIV Acquisition. Cogn Behav Pract (2017) 0.75
Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis. Sex Transm Dis (2016) 0.75
Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. J Int AIDS Soc (2016) 0.75
Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study. BMC Infect Dis (2017) 0.75
Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use. Contraception (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med (2008) 8.19
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep (2011) 4.85
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (2011) 3.61
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep (2012) 2.95
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
Antiretroviral prophylaxis: a defining moment in HIV control. Lancet (2011) 2.17
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Protecting the next generation--eliminating perinatal HIV-1 infection. N Engl J Med (2010) 1.42
Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One (2011) 1.40
Adherence, compliance, and HAART. AIDS Clin Care (1997) 1.40
Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care (2012) 1.26
Primary care and public health partnerships for implementing pre-exposure prophylaxis. Am J Prev Med (2013) 1.08
Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care (2006) 1.08
From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation. Am J Prev Med (2013) 0.96
HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings. Am J Prev Med (2013) 0.91
Serodiscordancy and HIV prevention in sub-Saharan Africa. Lancet (2013) 0.83
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr (2012) 3.44
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr (2015) 2.80
The Chinese free antiretroviral treatment program: challenges and responses. AIDS (2007) 2.73
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr (2014) 2.43
Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med (2013) 2.25
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One (2012) 1.84
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr (2007) 1.50
Use of antiretrovirals for HIV prevention: what do we know and what don't we know? Curr HIV/AIDS Rep (2013) 1.49
GPS-measured distance to clinic, but not self-reported transportation factors, are associated with missed HIV clinic visits in rural Uganda. AIDS (2013) 1.46
Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. Sex Transm Dis (2012) 1.41
Rethinking the "pre" in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS One (2012) 1.39
Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr (2013) 1.39
High acceptability for cell phone text messages to improve communication of laboratory results with HIV-infected patients in rural Uganda: a cross-sectional survey study. BMC Med Inform Decis Mak (2012) 1.36
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34
The Meanings in the messages: how SMS reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda. AIDS (2016) 1.30
How does antiretroviral treatment attenuate the stigma of HIV? Evidence from a cohort study in rural Uganda. AIDS Behav (2013) 1.21
Antiretroviral adherence during pregnancy and postpartum in Latin America. AIDS Patient Care STDS (2012) 1.20
Improving Adherence to Antiretroviral Therapy With Triggered Real-time Text Message Reminders: The China Adherence Through Technology Study. J Acquir Immune Defic Syndr (2015) 1.17
A pilot study of an mHealth application for healthcare workers: poor uptake despite high reported acceptability at a rural South African community-based MDR-TB treatment program. PLoS One (2013) 1.15
HIV prevention: great achievements, more challenges ahead. J Acquir Immune Defic Syndr (2013) 1.11
Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans. J Acquir Immune Defic Syndr (2014) 1.07
The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann Behav Med (2014) 1.07
Optimizing network connectivity for mobile health technologies in sub-Saharan Africa. PLoS One (2012) 1.04
HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods. AIDS (2013) 1.02
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges. AIDS Patient Care STDS (2014) 1.02
An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr (2014) 0.98
Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence. Sex Health (2010) 0.97
Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. J Acquir Immune Defic Syndr (2015) 0.96
Persistent HIV-related stigma in rural Uganda during a period of increasing HIV incidence despite treatment expansion. AIDS (2015) 0.95
HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods. J Acquir Immune Defic Syndr (2016) 0.94
Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis. Am J Prev Med (2013) 0.93
Treatment as long-term prevention: sustained reduction in HIV sexual transmission risk with use of antiretroviral therapy in rural Uganda. AIDS (2014) 0.91
Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr (2014) 0.90
Disinhibition in risky sexual behavior in men, but not women, during four years of antiretroviral therapy in rural, southwestern Uganda. PLoS One (2013) 0.90
CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda. AIDS (2014) 0.89
Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. AIDS Care (2014) 0.88
Understanding the role of age in HIV disclosure rates and patterns for HIV-infected children in southwestern Uganda. AIDS Care (2014) 0.86
Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. AIDS Behav (2015) 0.83
Sexual relationship power and malnutrition among HIV-positive women in rural Uganda. AIDS Behav (2012) 0.83
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav (2015) 0.83
Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr (2015) 0.82
No association found between traditional healer use and delayed antiretroviral initiation in rural Uganda. AIDS Behav (2013) 0.81
Dissemination of research findings to research participants living with HIV in rural Uganda: challenges and rewards. PLoS Med (2013) 0.81
Know your audience: predictors of success for a patient-centered texting app to augment linkage to HIV care in rural Uganda. J Med Internet Res (2015) 0.80
Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. AIDS (2016) 0.80
Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention. J Acquir Immune Defic Syndr (2017) 0.80
Explaining antiretroviral therapy adherence success among HIV-infected children in rural Uganda: a qualitative study. AIDS Behav (2015) 0.78
Structure and substrate specificity of the pyrococcal coenzyme A disulfide reductases/polysulfide reductases (CoADR/Psr): implications for S(0)-based respiration and a sulfur-dependent antioxidant system in Pyrococcus. Biochemistry (2013) 0.78
Declining prevalence of probable depression among patients presenting for antiretroviral therapy in rural Uganda: the role of early treatment initiation. AIDS Behav (2015) 0.78
Authors' Reply: Race and the Public Health Impact Potential of Pre-Exposure Prophylaxis in the United States. J Acquir Immune Defic Syndr (2015) 0.77
An expressive therapy group disclosure intervention for women living with HIV improves social support, self-efficacy, and the safety and quality of relationships: a qualitative analysis. J Assoc Nurses AIDS Care (2014) 0.77
The factor structure and presentation of depression among HIV-positive adults in Uganda. AIDS Behav (2015) 0.77
Lifetime HIV antiretroviral therapy adherence intervention: timing is everything: comment on "Managed problem solving for antiretroviral therapy adherence". JAMA Intern Med (2013) 0.76
HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda. AIDS (2016) 0.76
Medication Sharing is Rare among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. J Acquir Immune Defic Syndr (2017) 0.75
Tobacco use among adults initiating treatment for HIV infection in rural Uganda. AIDS Behav (2014) 0.75
D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Informing Strategies to Build PrEP Capacity among San Francisco Bay Area Clinicians. J Acquir Immune Defic Syndr (2016) 0.75
Adherence to antiretroviral prophylaxis during early infancy in Latin America. Braz J Infect Dis (2013) 0.75
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr (2016) 0.75
Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study. J Acquir Immune Defic Syndr (2015) 0.75
Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure. J Acquir Immune Defic Syndr (2017) 0.75
Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa? J Acquir Immune Defic Syndr (2017) 0.75
Changes in Kidney Function Associated with Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr (2017) 0.75
Technological methods to measure adherence to antiretroviral therapy and preexposure prophylaxis. Curr Opin HIV AIDS (2017) 0.75
Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention. J Acquir Immune Defic Syndr (2017) 0.75
CROI 2013: New tools to understand transmission dynamics and prevent HIV infections. Top Antivir Med (2013) 0.75
Prevalence and clinical impacts of HIV-1 intersubtype recombinants in uganda revealed by a near-full-genome population and deep sequencing approaches. AIDS (2017) 0.75